RxSight Inc. (RXST)
NASDAQ (NMS) NASDAQ (NMS) Primary 
RxSight, Inc. (RXST) Reports Q4 Loss, Beats Revenue Estimates
RxSight, Inc. (RXST) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.03 per share a year ago.
Earnings Preview: RxSight, Inc. (RXST) Q4 Earnings Expected to Decline
RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RxSight, Inc. (RXST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
RxSight, Inc. (RXST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
RxSight (RXST) Soars 14.1%: Is Further Upside Left in the Stock?
RxSight (RXST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
RxSight, Inc. (RXST) Q3 2025 Earnings Call Transcript
RxSight, Inc. ( RXST ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Oliver Moravcevic Ronald Kurtz - Co-President, CEO & Director Shelley Thunen - Co-President & CFO Conference Call Participants Iseult McMahon - BTIG, LLC, Research Division David Saxon - Needham & Company, LLC, Research Division Gursimran Kaur - Wells Fargo Securities, LLC, Research Division Patrick Wood - Morgan Stanley, Research Division K. Gong - JPMorgan Chase & Co, Research Division Adam Maeder - Piper Sandler & Co., Research Division Danielle Antalffy - UBS Investment Bank, Research Division Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Hello, everyone.
RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates
RxSight, Inc. (RXST) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to break-even earnings per share a year ago.
RxSight, Inc. (RXST) Q2 2025 Earnings Call Transcript
RxSight, Inc. (NASDAQ:RXST ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Oliver Moravcevic - Vice President of Investor Relations Ronald M. Kurtz - Co-President, CEO & Director Shelley B.
RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates
RxSight, Inc. (RXST) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to break-even earnings per share a year ago.
RxSight: Valuation Blowout Creates Opportunity
RxSight is a promising growth stock in the medical device sector, focusing on innovative cataract treatments with a large addressable market. Despite a recent decline, RxSight's high margins and scalable technology make it an attractive long-term investment, especially with expected 20% revenue growth in 2025. The stock's valuation has dropped from 20x to 4x trailing sales over the past year, presenting a potential buying opportunity for long-term investors.
RxSight, Inc. (RXST) Q1 2025 Earnings Call Transcript
RxSight, Inc. (NASDAQ:RXST ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Oliver Moravcevic - Vice President, Investor Relations Ron Kurtz - President & Chief Executive Officer Shelley Thunen - Chief Financial Officer Conference Call Participants Xuyang Li - Jefferies Patrick Wood - Morgan Stanley Steve Lichtman - Oppenheimer David Saxon - Needham & Company Adam Maeder - Piper Sandler Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Craig Bijou - Bank of America Tom Stephan - Stifel Operator Thank you for standing by. At this time, I would like to welcome everyone to the RxSight First Quarter 2025 Earnings Conference Call.
RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates
RxSight, Inc. (RXST) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.12 per share a year ago.
RxSight, Inc. (RXST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
